I am so interested, how PIII trial design will loo
Post# of 72440
With interim analysis or without ??
With "cross over" design or not
Trial end points being similar to PII or other important end points will be added eg. QoL ??
Will OM induced by chemo alone ( 5FU , topotecan and other drugs) will be added to expend the cohort of patients and by that quicken the trial and widen indications for B-OM beyond chemo-radiation
Very exiting times for all of us longs
aragon